Mitapivat Sulfate Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 5 mg, 20 mg, 50 mg

Reference Brands: Pyrukynd (USA)

Category: Anemia

Mitapivat Sulfate is available in Tablets and strengths such as 5 mg, 20 mg, 50 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Mitapivat Sulfate is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Mitapivat Sulfate can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Mitapivat sulfate is an oral, first-in-class pyruvate kinase activator used in the treatment of specific forms of anemia. Marketed under the brand name Pyrukynd, mitapivat is indicated for adults with hemolytic anemia caused by pyruvate kinase deficiency, a rare inherited disorder that leads to impaired red blood cell energy metabolism and premature red blood cell destruction. The medication is administered by mouth as the sulfate hydrate salt, offering a convenient oral treatment option for long-term disease management.

Mitapivat works by activating the pyruvate kinase enzyme in red blood cells, a key component of the glycolytic pathway responsible for generating cellular energy. By enhancing enzyme activity, mitapivat improves adenosine triphosphate (ATP) production, increases red blood cell survival, and reduces hemolysis. This results in improved hemoglobin levels and, in many patients, a decreased need for blood transfusions.

Mitapivat has demonstrated clinical benefit in patients with pyruvate kinase deficiency regardless of transfusion status. Its targeted mechanism of action represents a significant advancement in the treatment of inherited hemolytic anemias. With an established safety and efficacy profile, mitapivat sulfate provides a disease-specific therapeutic approach and plays an important role in improving clinical outcomes and quality of life for patients with pyruvate kinase deficiency–associated anemia.